Literature DB >> 17616479

Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization.

Zhiqiang Li1, Tiruneh K Hailemariam, Hongwen Zhou, Yan Li, Dale C Duckworth, David A Peake, Youyan Zhang, Ming-Shang Kuo, Guoqing Cao, Xian-Cheng Jiang.   

Abstract

Sphingomyelin plays a very important role both in cell membrane formation that may well have an impact on the development of diseases like atherosclerosis and diabetes. However, the molecular mechanism that governs intracellular and plasma membrane SM levels is largely unknown. Recently, two isoforms of sphingomyelin synthase (SMS1 and SMS2), the last enzyme for SM de novo synthesis, have been cloned. We have hypothesized that SMS1 and SMS2 are the two most likely candidates responsible for the SM levels in the cells and on the plasma membrane. To test this hypothesis, cultured cells were treated with tricyclodecan-9-yl-xanthogenate (D609), an inhibitor of SMS, or with SMS1 and SMS2 siRNAs. Cells were then pulsed with [14C]-L-serine (a precursor of all sphingolipids). SMS activity and [14C]-SM in the cells were monitored. We found that SMS activity was significantly decreased in cells after D609 or SMS siRNA treatment, compared with controls. SMS inhibition by D609 or SMS siRNAs significantly decreased intracellular [14C]-SM levels. We measured cellular lipid levels, including SM, ceramide, phosphatidylcholine, and diacylglycerol and found that SMS1 and SMS2 siRNA treatment caused a significant decrease of SM levels (20% and 11%, respectively), compared to control siRNA treatment; SMS1 but not SMS2 siRNA treatment caused a significant increase of ceramide levels (10%). There was a decreasing tendency for diacylglycerol levels after both SMS1 and SMS2 siRNA treatment, however, it was not statistical significant. As shown by lipid rafts isolation and lipid determination, SMS1 and SMS2 siRNA treatment led to a decrease of SM content in detergent-resistant lipid rafts on the cell membrane. Furthermore, SMS1 and SMS2 siRNA-treated cells had a stronger resistance than did control siRNA-treated cells to lysenin (a protein that causes cell lysis due to its affinity for plasma membrane SM). These results indicate that both SMS1 and SMS2 contribute to SM de novo synthesis and control SM levels in the cells and on the cell membrane including plasma membrane, implying an important relationship between SMS activity and cell functions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616479      PMCID: PMC2712822          DOI: 10.1016/j.bbalip.2007.05.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  43 in total

1.  Basic fibroblast growth factor-induced proliferation of primary astrocytes. evidence for the involvement of sphingomyelin biosynthesis.

Authors:  L Riboni; P Viani; R Bassi; P Giussani; G Tettamanti
Journal:  J Biol Chem       Date:  2001-01-22       Impact factor: 5.157

Review 2.  The therapeutic potential of modulating the ceramide/sphingomyelin pathway.

Authors:  Richard Kolesnick
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

3.  The synthesis of sphingomyelin in the Morris hepatomas 7777 and 5123D is restricted to the plasma membrane.

Authors:  A van den Hill; G P van Heusden; K W Wirtz
Journal:  Biochim Biophys Acta       Date:  1985-02-08

4.  Changes in the lipid turnover, composition, and organization, as sphingolipid-enriched membrane domains, in rat cerebellar granule cells developing in vitro.

Authors:  A Prinetti; V Chigorno; S Prioni; N Loberto; N Marano; G Tettamanti; S Sonnino
Journal:  J Biol Chem       Date:  2001-03-22       Impact factor: 5.157

5.  Identification of a family of animal sphingomyelin synthases.

Authors:  Klazien Huitema; Joep van den Dikkenberg; Jos F H M Brouwers; Joost C M Holthuis
Journal:  EMBO J       Date:  2003-12-18       Impact factor: 11.598

6.  Expression cloning of a human cDNA restoring sphingomyelin synthesis and cell growth in sphingomyelin synthase-defective lymphoid cells.

Authors:  Shohei Yamaoka; Michihiko Miyaji; Toshiyuki Kitano; Hisanori Umehara; Toshiro Okazaki
Journal:  J Biol Chem       Date:  2004-02-19       Impact factor: 5.157

7.  LMP2A does not require palmitoylation to localize to buoyant complexes or for function.

Authors:  Rebecca B Katzman; Richard Longnecker
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

8.  Chromatin sphingomyelin changes in cell proliferation and/or apoptosis induced by ciprofibrate.

Authors:  E Albi; S Pieroni; M P Viola Magni; C Sartori
Journal:  J Cell Physiol       Date:  2003-08       Impact factor: 6.384

9.  Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells.

Authors:  Aimin Meng; Chiara Luberto; Patrick Meier; Aiping Bai; Xiaofeng Yang; Yusuf A Hannun; Daohong Zhou
Journal:  Exp Cell Res       Date:  2004-01-15       Impact factor: 3.905

10.  A lipid-specific toxin reveals heterogeneity of sphingomyelin-containing membranes.

Authors:  Reiko Ishitsuka; Akiko Yamaji-Hasegawa; Asami Makino; Yoshio Hirabayashi; Toshihide Kobayashi
Journal:  Biophys J       Date:  2004-01       Impact factor: 4.033

View more
  55 in total

1.  Impaired de novo choline synthesis explains why phosphatidylethanolamine N-methyltransferase-deficient mice are protected from diet-induced obesity.

Authors:  René L Jacobs; Yang Zhao; Debby P Y Koonen; Torunn Sletten; Brian Su; Susanne Lingrell; Guoqing Cao; David A Peake; Ming-Shang Kuo; Spencer D Proctor; Brian P Kennedy; Jason R B Dyck; Dennis E Vance
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

2.  A toxin-based probe reveals cytoplasmic exposure of Golgi sphingomyelin.

Authors:  Biserka Bakrac; Ales Kladnik; Peter Macek; Gavin McHaffie; Andreas Werner; Jeremy H Lakey; Gregor Anderluh
Journal:  J Biol Chem       Date:  2010-05-12       Impact factor: 5.157

Review 3.  Remodeling of sphingolipids by plasma membrane associated enzymes.

Authors:  Massimo Aureli; Nicoletta Loberto; Vanna Chigorno; Alessandro Prinetti; Sandro Sonnino
Journal:  Neurochem Res       Date:  2010-12-23       Impact factor: 3.996

4.  Pharmacological Activation of Peroxisome Proliferator-Activated Receptor {Delta} Increases Sphingomyelin Synthase Activity in THP-1 Macrophage-Derived Foam Cell.

Authors:  Dongsheng Mou; Hua Yang; Changhua Qu; Juan Chen; Chaogui Zhang
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

5.  Sphingolipid metabolism regulates development and lifespan in Caenorhabditis elegans.

Authors:  Roy G Cutler; Kenneth W Thompson; Simonetta Camandola; Kendra T Mack; Mark P Mattson
Journal:  Mech Ageing Dev       Date:  2014-11-28       Impact factor: 5.432

Review 6.  Sphingolipids and lipid rafts: Novel concepts and methods of analysis.

Authors:  Erhard Bieberich
Journal:  Chem Phys Lipids       Date:  2018-09-05       Impact factor: 3.329

Review 7.  Integration of cytokine biology and lipid metabolism in stroke.

Authors:  Rao Muralikrishna Adibhatla; Robert Dempsy; James Franklin Hatcher
Journal:  Front Biosci       Date:  2008-01-01

8.  Sphingomyelin synthase 2 is one of the determinants for plasma and liver sphingomyelin levels in mice.

Authors:  Jing Liu; Hongqi Zhang; Zhiqiang Li; Tiruneh K Hailemariam; Mahua Chakraborty; Kailiu Jiang; Daniel Qiu; Hai H Bui; David A Peake; Ming-Shang Kuo; Raj Wadgaonkar; Guoqing Cao; Xian-Cheng Jiang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-03-12       Impact factor: 8.311

9.  The domain responsible for sphingomyelin synthase (SMS) activity.

Authors:  Calvin Yeang; Shweta Varshney; Renxiao Wang; Ya Zhang; Deyong Ye; Xian-Cheng Jiang
Journal:  Biochim Biophys Acta       Date:  2008-07-23

10.  Sphingomyelin synthase 2 but not sphingomyelin synthase 1 is upregulated in ovarian cancer and involved in migration, growth and survival via different mechanisms.

Authors:  Fang Jing; Chao Jing; Xiaoyan Dai; Guang Zhou; Shi Di; Xiaoxia Bi; Tingting Dai; Tingting Qin; Li Hong
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.